Get started

Financials · CRSP

CRISPR Therapeutics AG (CRSP) financials

For the twelve months ended Sep 30, 2026, CRISPR Therapeutics AG reported $25.17M of revenue and -$456.13M of net income.

Revenue, TTM
$25.17M
Revenue growth, YoY
-34.3%
Net income, TTM
-$456.13M
Net margin
-1812.1%
Free cash flow, TTM
-$376.71M
EPS, diluted, TTM
-$4.69
Cash
$192.03M
Total debt
$586.93M
P/S
173.99
Market cap
$4.38B
Annual revenue$3.51M
FY2016FY2025
Annual net income-$581.60M
FY2016FY2025
Annual free cash flow-$345.93M
FY2016FY2025

CRSP revenue and earnings growth

CRSP revenueQ3 2026$12.67M

Quarter YoY
14x
QoQ
+24.4%
FY YoY
-90.6%
5Y CAGR
+37.3%
10Y CAGR
+30.4%

CRSP revenue was $12.67M in fiscal Q3 2026 (ended Sep 30, 2026), up about 14-fold from a year earlier and up 24.4% from the prior quarter. For the full fiscal 2025 it was $3.51M, down 90.6% from fiscal 2024. Compound annual growth was +37.3% over 5 years and +30.4% over 10 years. It rose in 5 of the last 10 fiscal years.

CRSP net incomeQ3 2026-$111.44M

CRSP net income was -$111.44M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$106.44M a year earlier. For the full fiscal 2025 it was -$581.60M, compared with -$366.25M in fiscal 2024.

CRSP EPSQ3 2026-$1.15

CRSP diluted EPS was -$1.15 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.17 a year earlier. For the full fiscal 2025 it was -$6.47, compared with -$4.34 in fiscal 2024.

CRSP free cash flowQ3 2026-$90.10M

CRSP free cash flow was -$90.10M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$84.71M a year earlier. For the full fiscal 2025 it was -$345.93M, compared with -$144.68M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$3.51M$37.31M$371.21M$1.20M$914.96M$719.0K$289.59M$3.12M$41.00M$5.16M
Research and development$284.81M$310.24M$387.33M$461.64M$340.57M$221.38M$179.36M$113.77M$69.80M$42.24M
Selling, general and admin$73.54M$72.98M$76.16M$102.46M$99.69M$85.75M$63.49M$48.29M$35.84M$31.06M
Operating income-$664.57M-$466.57M-$222.54M-$673.16M$373.53M-$354.44M$46.74M-$158.94M-$64.65M-$68.13M
Pre-tax income-$577.97M-$362.67M-$150.72M-$650.50M$379.53M-$348.06M$67.31M-$164.43M-$66.61M-$22.72M
Income tax$3.63M$3.59M$2.89M-$325.0K$1.87M$809.0K$448.0K$553.0K$1.75M$484.0K
Net income-$581.60M-$366.25M-$153.61M-$650.17M$377.66M-$348.87M$66.86M-$164.98M-$68.36M-$23.18M
EPS, basic-$6.47-$4.34-$1.94-$8.36$4.97-$5.29$1.23-$3.44-$1.71-$1.89
EPS, diluted-$6.47-$4.34-$1.94-$8.36$4.70-$5.29$1.17-$3.44-$1.71-$1.89
Diluted shares89.9M84.4M79.2M77.7M80.4M65.9M56.9M48.0M40.1M12.3M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$347.56M$298.26M$389.48M$211.88M$923.03M$1.17B$943.77M$456.65M$239.76M$315.52M
Short-term investments$1.63B$1.61B$1.30B$1.60B$1.46B$521.71M$0---
Receivables$0$25.00M$200.00M$0$305.0K$144.0K$99.0K$88.0K$2.63M$3.16M
Current assets$1.99B$1.94B$1.91B$1.85B$2.42B$1.72B$987.55M$466.39M$248.38M$320.19M
Total assets$2.27B$2.24B$2.23B$2.24B$2.75B$1.83B$1.07B$489.02M$271.35M$344.96M
Current liabilities$149.12M$87.78M$108.79M$121.11M$119.88M$94.26M$57.11M$27.75M$14.51M$22.00M
Total debt$0---------
Total liabilities$343.43M$309.95M$346.77M$367.58M$352.42M$163.73M$127.33M$96.82M$83.51M$112.12M
Shareholders' equity$1.92B$1.93B$1.88B$1.88B$2.40B$1.66B$939.42M$392.19M$187.83M$232.85M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$345.01M-$142.77M-$260.38M-$495.74M$538.97M-$238.37M$56.68M-$96.24M-$70.09M-$52.86M
Capital expenditures$914.0K$1.90M$9.47M$37.19M$81.70M$18.36M$6.68M$2.77M$7.81M$3.02M
Free cash flow-$345.93M-$144.68M-$269.85M-$532.93M$457.27M-$256.72M$49.99M-$99.01M-$77.91M-$55.88M
Investing cash flow-$31.80M-$280.48M$374.65M-$258.65M-$1.04B-$541.17M$1.32M-$2.77M-$8.31M$31.88M
Financing cash flow$426.03M$331.98M$62.66M$38.59M$250.94M$1.02B$430.98M$315.93M$2.61M$183.22M
Share repurchases-------$57.0K--
Stock-based compensation$72.50M$86.57M$81.03M$97.95M$102.39M$66.02M$44.06M$34.98M$18.87M$10.84M
Depreciation and amortization$19.48M$19.26M$19.84M$24.17M$17.95M$9.18M$4.72M$3.52M$3.02M$925.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-90.6%-89.9%30885.5%-99.9%127154.9%-99.8%9169.8%-92.4%693.9%1990.7%
Operating margin-18933.6%-1250.4%-60.0%-56190.4%40.8%-49295.5%16.1%-5087.8%-157.7%-1319.3%
Net margin-16569.8%-981.5%-41.4%-54271.7%41.3%-48520.9%23.1%-5281.1%-166.7%-448.8%
Free cash flow margin-9855.5%-387.7%-72.7%-44484.9%50.0%-35705.7%17.3%-3169.4%-190.0%-1082.0%
Return on equity-30.3%-19.0%-8.2%-34.7%15.7%-21.0%7.1%-42.1%-36.4%-10.0%
Return on assets-25.7%-16.3%-6.9%-29.0%13.7%-19.1%6.3%-33.7%-25.2%-6.7%
Current ratio13.3222.0717.5415.3020.1718.2117.2916.8117.1214.56
Debt to equity0.00---------

Source: XBRL data CRISPR Therapeutics AG files with the SEC, latest filing dated Nov 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CRSP peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CRSP$25.17M-34.3%-$456.13M-1812.1%$4.38B
EDIT$49.83M+7.4%-$72.22M-145.0%$385.5M
NTLA$52.89M-8.1%-$426.14M-805.7%$1.57B
VRTX$12.95B+10.5%$3.98B30.7%$138.91B
BEAM$146.64M+163.3%-$108.35M-73.9%$2.60B
SRPT$1.96B-18.9%-$114.62M-5.9%$1.76B
CRBU$9.44M+1.6%-$102.47M-1085.0%$44.3M
ALLO$6.94M+269.5%-$174.46M-2513.9%$322.2M

CRSP FAQ

8 questions
  • What is CRSP revenue?
    CRISPR Therapeutics AG (CRSP) reported $25.17M of revenue for the twelve months ended Sep 30, 2026. That is down 34.3% from the year before. Revenue for fiscal 2025 was $3.51M.
  • Is CRSP profitable?
    No. CRISPR Therapeutics AG reported a net loss of $456.13M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does CRSP have?
    CRISPR Therapeutics AG reported $192.03M in cash and cash equivalents and $586.93M of debt on its most recent balance sheet in SEC filings.
  • How fast is CRSP revenue growing?
    CRISPR Therapeutics AG's revenue changed -90.6% in fiscal 2025, to $3.51M. Its compound annual growth rate was +37.3% over 5 years and +30.4% over 10 years.
  • What is CRSP free cash flow?
    CRISPR Therapeutics AG generated -$376.71M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$374.63M less capital expenditures.
  • What is CRSP earnings per share?
    Diluted earnings per share were -$4.69 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CRSP last report financial results?
    The latest statements here come from CRISPR Therapeutics AG's 10-Q filed on Nov 2, 2026, covering the period ended Sep 30, 2026.
  • Where does this CRSP financial data come from?
    Quantisnow builds these statements from the structured XBRL data CRISPR Therapeutics AG files with the SEC. It is provided for information only and is not investment advice.